ArticleBritish journal of cancer2014

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.

E X Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.